LeMaitre Vascular (NASDAQ:LMAT) Releases Q2 2024 Earnings Guidance

LeMaitre Vascular (NASDAQ:LMAT) issued an update on its second quarter 2024 earnings guidance on Friday morning. The company provided earnings per share guidance of 0.450-0.500 for the period, compared to the consensus earnings per share estimate of 0.440. The company issued revenue guidance of $53.7 million-$56.1 million, compared to the consensus revenue estimate of $54.3 million. LeMaitre Vascular also updated its FY 2024 guidance to 1.730-1.840 EPS.

LeMaitre Vascular Trading Up 11.2 %

Shares of LeMaitre Vascular stock opened at $74.22 on Monday. The company’s fifty day simple moving average is $65.93 and its 200-day simple moving average is $58.85. The company has a market cap of $1.67 billion, a price-to-earnings ratio of 49.15, a PEG ratio of 2.99 and a beta of 0.88. LeMaitre Vascular has a 1 year low of $44.27 and a 1 year high of $74.64.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings data on Thursday, May 2nd. The medical instruments supplier reported $0.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.39 by $0.05. The business had revenue of $53.48 million for the quarter, compared to the consensus estimate of $51.50 million. LeMaitre Vascular had a net margin of 16.99% and a return on equity of 11.57%. LeMaitre Vascular’s quarterly revenue was up 13.6% on a year-over-year basis. During the same quarter last year, the company posted $0.27 earnings per share. As a group, research analysts forecast that LeMaitre Vascular will post 1.77 earnings per share for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, May 30th. Investors of record on Thursday, May 16th will be given a $0.16 dividend. The ex-dividend date is Wednesday, May 15th. This represents a $0.64 annualized dividend and a yield of 0.86%. LeMaitre Vascular’s dividend payout ratio (DPR) is currently 42.38%.

Analyst Upgrades and Downgrades

Several research analysts recently commented on LMAT shares. KeyCorp started coverage on LeMaitre Vascular in a research report on Tuesday, February 6th. They issued a sector weight rating for the company. StockNews.com raised LeMaitre Vascular from a hold rating to a buy rating in a research report on Friday. Barrington Research raised their target price on LeMaitre Vascular from $69.00 to $79.00 and gave the stock an outperform rating in a research report on Friday. JMP Securities lifted their price objective on LeMaitre Vascular from $72.00 to $77.00 and gave the company a market outperform rating in a report on Friday. Finally, Stifel Nicolaus raised LeMaitre Vascular from a hold rating to a buy rating and lifted their price objective for the company from $59.00 to $75.00 in a report on Friday, April 26th. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of Moderate Buy and a consensus price target of $73.83.

Insider Activity at LeMaitre Vascular

In related news, Director John A. Roush sold 7,500 shares of LeMaitre Vascular stock in a transaction dated Thursday, March 7th. The stock was sold at an average price of $69.00, for a total value of $517,500.00. Following the completion of the transaction, the director now directly owns 2,278 shares of the company’s stock, valued at $157,182. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, Director John A. Roush sold 7,500 shares of the firm’s stock in a transaction dated Thursday, March 7th. The shares were sold at an average price of $69.00, for a total value of $517,500.00. Following the transaction, the director now owns 2,278 shares of the company’s stock, valued at approximately $157,182. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Lawrence J. Jasinski sold 5,110 shares of LeMaitre Vascular stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $67.50, for a total transaction of $344,925.00. Following the sale, the director now directly owns 5,309 shares of the company’s stock, valued at approximately $358,357.50. The disclosure for this sale can be found here. Insiders sold 114,036 shares of company stock valued at $7,873,749 over the last ninety days. 10.79% of the stock is owned by insiders.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.